Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Plays Misdemeanor Card In Adulterated Supplement Prosecution

This article was originally published in The Tan Sheet

Executive Summary

FDA's Office of Criminal Investigations assists in prosecuting the maker of "all-natural" sexual enhancement drugs, an action in line with its strategy to seek more misdemeanor charges against violative food and drug firms
Advertisement

Related Content

Leahy Loads Congressional Food Safety Plate With Criminal Charges Bill
Leahy Loads Congressional Food Safety Plate With Criminal Charges Bill
Leahy Loads Congressional Food Safety Plate With Criminal Charges Bill
FDA Targeting Execs With Criminal Charges For Adulterated/Misbranded Goods
FDA Targeting Execs With Criminal Charges For Adulterated/Misbranded Goods
FDA Targets Executives With Powerful Misdemeanor Strategy
FDA Targets Executives With Powerful Misdemeanor Strategy
FDA Targets Executives With Powerful Misdemeanor Strategy
USADA Builds Team To Change Supplement Law, Cites "Lax" Regulations
Sharfstein Says Spiked Products Top FDA Supplement Enforcement Goals

Topics

Advertisement
UsernamePublicRestriction

Register

PS104037

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel